http://www.mission3.com/press/news Tue, 20 Jun 2006 16:48:00 GMT RSS feed for Mission3, Inc. <p>Phoenix, AZ - June 19, 2006 - Mission3, Inc., a leading provider of document and project management software serving the Life Sciences industry announced today that they have joined a strategic partnership with TGen Drug Development Services (TD2), the non-profit drug development affiliate of the Translational Genomics Research Institute (TGen) to aid in developing oncology therapeutics.</p> <p>"MissionFire allows Life Science organizations to manage their mission-critical content and processes in a cost effective manner. This enterprise software application enables companies to take control of their project management and documentation in one centralized web-based environment, allowing for an efficient and effective use of resources. With rich features in project management and document management, it was designed specifically for the Life Sciences industry to facilitate electronic submissions with the FDA", said Dirk Karsten Beth, President of Mission3, Inc.</p> <p>"This software is a valuable tool that will help us get promising new cancer treatments to patients as quickly and safely as possible, while continuing to meet stringent Federal regulations," said TD2 General Manager Steve Marsh.</p> <p>These companies are collaborating to bring together the drug development experience of TD2 and the software development expertise of Mission3, Inc. The resulting product will be an organized enterprise through the integration of project management and document management on a single platform with accountability and oversight through the entire drug development process. In return, TD2 will influence future versions of MissionFire.</p> Tue, 20 Jun 2006 16:48:00 GMT Mission3, Inc. <p> Philadelphia, PA (PRWEB) June 20, 2006 -- Adlib Software, a market leader in document transformation and workflow solutions, today announced an agreement with Mission3, Inc. that will see Adlib technology become the document transformation engine for Mission3's industry-leading suite of enterprise applications. Mission3, Inc. has specifically engineered MissionFire and FastCrossing for the Life Sciences industry to organize efforts around project and document management as well as facilitating electronic submissions to regulatory oversight bodies. </p> <p> Adlib's powerful Express Server and Exponent applications will greatly enhance Mission3, Inc.'s MissionFire enterprise project collaboration and document management offering by adding the ability to create PDF renditions from a wide variety of document types. Renditions are triggered automatically based on the value of each document's metadata. </p> <p> "Adlib's broad support for transforming Microsoft Word documents into submission ready PDFs is of significant importance to Mission3," said Dirk Karsten Beth, Founder and President of Mission3, Inc. "Using XML Job Tickets allows us to specify the required document transformation operations on a document by document basis and Exponent's web service interface accelerated our integration efforts." </p> <p> Adlib Express also enhances Mission3's FastCrossing offering by enabling rendering support for FDA compliant PDFs. "Adlib has a great product and their team is very easy to work with," Mr. Beth said. "We believe that Adlib technology can give us a competitive advantage by reducing time to market for our customers, as well as, maintaining compliance with regulations". </p> <p> "We are very excited to be embarking on this venture with Mission3," said Cameron Bramwell, Adlib's President and CEO. "Mission3 is an innovative company and an ideal partner for Adlib in this important market." </p> <p> A fully integrated version of FastCrossing with Adlib is due out in July of 2006. </p> <p> About Adlib <br> A market leader in document transformation and document workflow automation, Adlib Software includes many Fortune 500 companies and leading global organizations as its customers. Adlib products are used in applications ranging from document rendering and stamping to compound document and report level publishing of industries including Life Sciences, Financial Services, Legal and Manufacturing. <br> <br> Our customers rely on Adlib for reliable and flexible solutions for their complex and ever-evolving document transformation needs. <br> www.adlibsoftware.com </p> <p> About Mission3 <br> <br> Mission3 was founded to assist biotech, pharmaceutical, and medical device companies bring much-needed drugs, therapies and devices to market. Mission3's advanced suite of enterprise applications, MissionFire and FastCrossing, allow companies to manage bioscience projects, comply with FDA and other regulatory agency requirements, and submit FDA applications in an automated and managed environment. </p> <p> <br/> Contact Information: <br/> Christopher Brassington<br/> Vice President of Sales<br/> Mission3, Inc.<br/> www.mission3.com<br/> 602-957-2150 ext. 505<br/> cbrassington @ mission3.com</br> </p> <p> Peter Duff<br/> Vice President of Marketing<br/> Adlib Software<br/> www.adlibsoftware.com<br/> </p> Wed, 28 Jun 2006 23:01:00 GMT Mission3, Inc. <p><strong>Phoenix, AZ -August 28, 2006 -</strong> Mission3, Inc., a leading provider of document and project management software serving the Life Sciences industry, and Global Life Sciences, Inc. (GLS), a distinguished provider of business management consulting and IT solutions to the Life Sciences, announced today they have entered into a strategic partnership to address critical technology needs within the industry. With GLS's unparalleled expertise, along with their trusted IT practices and standards, and Mission3's robust suite of project planning, collaboration, and regulatory electronic submission applications, the alliance promises to provide much needed IT solutions to the international Life Sciences community. </p> <p> "We are extremely excited to have a partner like GLS. Their expertise, partnered with our enterprise suite of software, is perfectly tailored for the regulatory environment of the Life Sciences industry. GLS clientele can benefit immediately from the Web-based, collaborative environment that our products enable, providing the right people with access to the right data, at the right time, and most importantly, in the right context." said Dirk Karsten Beth, President of Mission3.</p> <p> The partnership of GLS and Mission3 will enable Life Science organizations to better manage aspects of the product life-cycle across the enterprise, from pre-clinical studies to post-market activities, through a cost-effective enterprise software solution that not only improves productivity but also simplifies the regulatory filing process unique to the industry.</p> <p> Designed specifically for the Life Sciences industry, Mission3's software suite, together with GLS's existing portfolio of integrated enterprise-wide services, will offer the broadest spectrum of IT solutions to the market.</p> <p> "Mission3 has developed an exciting and robust solution for the highly regulated Life Sciences industry," said Howard Asher, President and CEO of Global Life Sciences, Inc. "With Mission3 solutions, our clients can bring immensely helpful structure to the complex development of new medical products. In addition, these products scale from discovery all the way to the patient, which is critical for small organizations to global corporations."</p> <p> Under the new partnership, Mission3 and GLS will cooperate on sales and marketing as well as business development, and provide both organizations with an opportunity to expand their rapidly growing Life Science customer base. </p> <b> About Mission3, Inc.</b> <br> Mission3 was founded to assist biotech, pharmaceutical, and medical device companies bring much-needed drugs, therapies and devices to market. Mission3's advanced suite of enterprise applications, MissionFire and FastCrossing, allow companies to manage bioscience projects, comply with FDA and other regulatory agency requirements, and submit FDA applications in an automated and managed environment. </p> <p> <b>About Global Life Sciences</b><br> Global Life Sciences, Inc. (GLS) provides professional consulting services and IT solutions to the full spectrum of organizations within the life sciences industry. These solutions offer a wide array of hardware and enterprise class software designed explicitly for the life sciences regulated industry. GLS leadership is comprised of highly experienced executives in the worldwide life sciences industrial sector.</p> <br> <p><b>CONTACT INFORMATION:</b> <br> <br> Chris Joslin<br/> Vice President of Operations<br/> Mission3, Inc.<br/> www.mission3.com<br/> 602-957-2150 ext. 508<br/> cjoslin@mission3.com<br/> <br> <br> Gabriel Porras<br/> Director of Operations<br/> Global Life Sciences, Inc.<br/> www.glifesciences.com<br/> (858) 259-0000 ext. 105<br/> gabriel.porras@glifesciences.com<br/> </p> Mon, 28 Aug 2006 21:27:00 GMT Mission3, Inc. <html> <p> <b>Phoenix, AZ - September 25, 2006 -</b> Mission3, Inc., a leading provider of Document and Project Management software serving the Life Sciences industry announced today that it has published a new whitepaper on Document Integrity. </p> <p> Entitled, "Document Integrity in the Life Sciences: An Industry at Risk", the paper details document integrity and security issues that are critical to ensuring regulatory compliance for Life Sciences companies that are seeking product approval from the FDA. </p> <p> "With the amount of time and money invested in the product development timeline, which is nearing a billion dollars for a typical compound, I find it amazing that companies continue to treat their data and product information in such a haphazard way", said Dirk Karsten Beth, President of Mission3. </p> <p> The paper explores the solutions available in creating a collaborative environment, without introducing the unnecessary risk and lack of data integrity associated with email attachments and network file shares. "Document Integrity in the Life Sciences: An Industry at Risk" is a must read for anyone taking a compound from conception to FDA approval. </p> <p> The whitepaper is available for review and downloading at http://www.mission3.com. </p> <p> <b> About Mission3, Inc.</b> Mission3 was founded to assist biotech, pharmaceutical, and medical device companies bring much-needed drugs, therapies and devices to market. Mission3's advanced suite of enterprise applications, MissionFire and FastCrossing, allow companies to manage bioscience projects, comply with FDA and other regulatory agency requirements, and submit FDA applications in an automated and managed environment. </p> <p> <b> CONTACT INFORMATION:</b><br/> Chris Joslin<br/> Vice President of Operations<br/> Mission3, Inc.<br/> www.mission3.com<br/> 602-957-2150 ext. 508<br/> cjoslin@mission3.com<br/> Mon, 25 Sep 2006 17:41:00 GMT Mission3, Inc. <p> <b> FOR IMMEDIATE RELEASE </b> </p> <p> <b>Phoenix, AZ - October 11, 2006 -</b> Mission3, Inc., a leading provider of Document and Project Management software serving the Life Sciences industry and its partner, Global Life Sciences Inc. announce that the Life Sciences Information Technology Global Institute (LSIT) has chosen one of Mission3's flagship products, MissionFire, for its extensive document management needs. </p> <p> MissionFire is an enterprise grade software application that enables Life Sciences organizations to take control of their project management and documentation in one centralized, scalable, web-base environment, allowing for an efficient and effective use of resources.</p> <p> "MissionFire allows organizations to manage their mission-critical documents and processes in a cost effective, collaborative manner. It will help further LSIT's mission of creating open, publicly available Good Information Practices (GIP) for the Life Sciences community by centrally locating documents and information while facilitating secure collaboration among LSITs members", said Dirk Karsten Beth, President of Mission3.</p> <p> Membership in LSIT comes from a broad and diverse group of Life Sciences, Academia, and Research organizations, such as Pfizer, Novartis, and Amylin Pharmaceuticals, as well as University of California, San Diego, and Frost & Sullivan.</p> <p> Anette Asher, Executive Director of LSIT believes MissionFire will play a vital role in the development of GIP. "We are building a document that addresses compliance in an IT environment for life science and healthcare companies. Having a system like MissionFire to manage the project and all of our supporting documents is critical to our success," said Asher. "The best part for LSIT is that Mission3 and GLS have provided us with a software solution that is clearly built around the best practices promoted by our organization." </p> <p><b> About Mission3, Inc.</b><br> Mission3 was founded to assist biotech, pharmaceutical, and medical device companies bring much-needed drugs, therapies and devices to market. Mission3's advanced suite of enterprise applications, MissionFire and FastCrossing, allow companies to manage bioscience projects, comply with FDA and other regulatory agency requirements, and submit FDA applications in an automated and managed environment. </p> <p><b> About Global Life Sciences</b><br> Global Life Sciences, Inc. (GLS) provides professional consulting services and IT solutions to the full spectrum of organizations within the life sciences industry. These solutions offer a wide array of hardware and enterprise class software designed explicitly for the life sciences regulated industry. GLS leadership is comprised of highly experienced executives in the worldwide life sciences industrial sector.</p> <p><b> CONTACT INFORMATION:</b><br> Chris Joslin<br> Vice President of Operations<br> Mission3, Inc.<br> www.mission3.com<br> 602-957-2150 ext. 508<br> cjoslin@mission3.com<br> <br> Gabriel Porras<br> Director of Operations<br> Global Life Sciences, Inc.<br> www.glifesciences.com<br> (858) 259-0000 ext. 105<br> gabriel.porras@glifesciences.com<br> Wed, 11 Oct 2006 16:40:00 GMT Mission3, Inc. <p> <b>FOR IMMEDIATE RELEASE</b> </p> <p> <b> Phoenix, AZ - November 14, 2006 -</b> Mission3, Inc., a leading provider of Project and Document Management software serving the Life Sciences industry announced today that is has released the latest version of its integrated project and document management enterprise software, MissionFire. </p> <p> MissionFire enables Life Sciences organizations to take control of their project management and documentation in one secure, centralized, scalable web-base environment, allowing for an efficient and effective use of resources. It offers an improved user interface that allows the customer to configure various types of metadata for documents, making them significantly easier to classify for later retrieval. Renditions such as PDF files can be stored against a version of a file managed in MissionFire, allowing companies to submit regulatory applications with greater ease and speed. This latest release also allows customers to specify electronic signature reasons for each individual user. </p> <p> "This latest release of MissionFire further equips Life Sciences companies to successfully address the efficiency and cost pressures of their product development pipeline by providing a solid project and document management platform. MissionFire fosters increased collaboration and data management not only within an organization, but also across geographic distances", said Dirk Karsten Beth, President of Mission3. "Our solution reduces product development time and costs through process management as well as the allocation of resources needed in a cost-effective, efficient manner. This new release furthers our mission to provide the Life Sciences industry with solutions that are specifically designed for their unique needs." </p> <p> <b> About Mission3, Inc.</b><br> Mission3 was founded to assist biotech, pharmaceutical, and medical device companies with bringing much-needed drugs, therapies and devices to market. Mission3's advanced suite of enterprise applications, MissionFire and FastCrossing, allow companies to manage bioscience projects, comply with regional regulatory requirements, and submit regulated applications, regardless of region, in an automated and managed environment. </p> <p> <b> CONTACT INFORMATION:</b><br> Chris Joslin<br /> Vice President of Operations<br /> Mission3, Inc.<br /> www.mission3.com<br /> 602-957-2150 ext. 508<br /> cjoslin@mission3.com<br /> </p> Tue, 14 Nov 2006 17:50:00 GMT Mission3, Inc. <p> <b> FOR IMMEDIATE RELEASE </b> </p> <p> <b>Phoenix, AZ - January 22, 2007 - </b>Mission3, Inc., a leading provider of enterprise Project, Document, and e-Submission management software serving the Life Sciences industry announced today that has released its latest application, PDFRenditioning. </p> <p> PDFRenditioning is a PDF creation application that is fully integrated into Mission3's platform tools - MissionFire and FastCrossing. The application allows for the automated conversion of over 300 file types to PDF while supporting Life Sciences specific output standards. Those files are then associated with their source documents in MissionFire where they are always available and quickly retrievable, making any document request significantly easier, whether a regulatory filing or facilitating an FDA inspection. PDFRenditioning was built to handle the specifications set forth by the FDA and other international regulatory bodies.</p> <p> "PDFRenditioning is a critical part of Mission3's innovative enterprise suite of project, document, and e-Submission management tools that add order to a difficult product development and regulatory submission process. This technology can automatically create PDF documents that meet regulatory guidance, including proper bookmarks and links. Companies using PDFRenditioning in harmony with MissionFire and FastCrossing can truly gain a competitive advantage in the development process by reducing the amount of time needed to develop and submit a product for regulatory approval." said Dirk Karsten Beth, President of Mission3. </p> <p> <b>About Mission3, Inc.</b><br> Mission3 was founded to assist biotech, pharmaceutical, and medical device companies to bring needed therapies and devices to market quickly and efficiently. Its advanced enterprise software suite allows companies to manage projects and documents; comply with regulatory requirements; and submit applications in an automated, electronic, and managed environment. Companies taking full advantage of Mission3's industry leading enterprise software suite can simultaneously create an electronic submission while a project is underway, significantly reducing the time needed to develop a product and submit it for regulatory approval. </p> <p><b> CONTACT INFORMATION:</b><br> Chris Joslin<br> Vice President of Operations<br> Mission3, Inc.<br> www.mission3.com<br> 602-957-2150 ext. 508<br> cjoslin@mission3.com<br> </p> Mon, 22 Jan 2007 16:58:00 GMT Mission3, Inc. <p> <b>FOR IMMEDIATE RELEASE</b> </p> <p> <b> Philadelphia, PA - February 7, 2007 -</b> Mission3, Inc., a leading provider of Project and Document Management and e-submission software specifically serving the Life Sciences industry announced today that is has reached a significant milestone in the development of its enterprise software suite with the latest release of FastCrossing.</p> <p> FastCrossing is an electronic submission management application that allows Life Sciences companies to manage their mission critical regulatory submissions, in parallel with their project development, for the FDA as well as European, Canadian, and Japanese counterparts. FastCrossing is a Web-based application that allows for rapid implementation and provides a logical means for controlling specific submission information such as type (NDA, IND, or ANDA) as well as region.</p> <p> User friendly, FastCrossing assembles and delivers valid eCTD XML and supporting files and folders with the push of a button. It uses a database to store all configurations, making it significantly faster than applications that manage the submission on a file system or in native XML. </p> <p> "A unique feature of FastCrossing is cloning, the creation of derivative submissions, for regional submissions or new indications. Cloning allows users to select for editing only those parts of a submission that they need to change, allowing the remainder to inherit changes from the original. When coupled with MissionFire's project and document management capabilities, FastCrossing fulfills the requirements of creating an 'Organized Enterprise', ensuring time to market advantage and increasing shareholder value." said Dirk Karsten Beth, President of Mission3.</p> <p> <b> About Mission3, Inc.</b><br> Mission3 was founded to assist biotech, pharmaceutical, and medical device companies to bring needed therapies and devices to market quickly and efficiently. Its advanced enterprise software suite allows companies to manage projects and documents; comply with regulatory requirements; and submit applications in an automated, electronic, and managed environment. Companies taking full advantage of Mission3's industry leading enterprise software suite can simultaneously create an electronic submission while a project is underway, significantly reducing the time needed to develop a product and submit it for regulatory approval. </p> <p> <b> CONTACT INFORMATION:</b><br> Chris Joslin<br> Vice President of Operations<br> Mission3, Inc.<br> www.mission3.com<br> 602-957-2150 ext. 508<br> cjoslin@mission3.com<br> </p> Wed, 07 Feb 2007 16:33:00 GMT Mission3, Inc. <p> <b>FOR IMMEDIATE RELEASE</b> </p> <p> <b>Phoenix, AZ – March 16, 2007 – </b>Mission3, Inc., a leading provider of Regulated Product Development enterprise software specifically serving the Life Sciences industry, announced today that it is integrating its Electronic Submission Management application, FastCrossing, with Oracle’s complete technology stack.</p> <p? FastCrossing lets Life Sciences companies submit applications to the FDA and other global regulatory bodies in a compliant electronic format. It offers industry-leading standards compliance and unique features that add significant business value. Cloning allows Life Science companies to manage submissions to multiple regions, dosages, or indications with little more effort than managing a single submission. Early binding, early linking, compare, real-time validation, and a web-based interface make FastCrossing incredibly valuable to customers.</p> <p> "By integrating with the Oracle E-Business Suite, FastCrossing will be able to leverage data from their source in multiple systems across the enterprise." said Dirk Karsten Beth, President and Founder of Mission3.</p> <p>"Oracle is emphasizing Life Sciences and the partnership with Mission3 strengthens our presence in the Life Sciences industry and gives our customers a great extension of their investment with Oracle." said Ron Huddleston, Senior Director, ISVs at Oracle.</p> <p> <b> About Mission3, Inc.</b><br> Mission3 was founded to assist biotech, pharmaceutical, and medical device companies to bring needed therapies and devices to market quickly and efficiently. Its advanced enterprise software suite allows companies to manage projects and documents; comply with regulatory requirements; and submit applications in an automated, electronic, and managed environment. Companies taking full advantage of Mission3’s industry leading enterprise software suite can simultaneously create an electronic submission while a project is underway, significantly reducing the time needed to develop a product and submit it for regulatory approval. </p> <p> <b>About the Oracle PartnerNetwork</b><br> Oracle PartnerNetwork is a global business network of more than 19,000 companies who deliver innovative software solutions based on Oracle software. Through access to Oracle’s premier products, education, technical services, marketing and sales support, the Oracle PartnerNetwork program provides partners with the resources they need to be successful in today’s global economy. Oracle partners are able to offer to their customers, leading-edge solutions backed by Oracle’s position as the world’s largest enterprise software company. Partners who are able to demonstrate superior product knowledge, technical expertise and a commitment to doing business with Oracle can qualify for the Oracle Certified Partner Levels. http://oraclepartnernetwork.oracle.com</p> <p> Trademarks<br> Oracle is a registered trademark of Oracle Corporation and/or its affiliates.</p> <p> <b> CONTACT INFORMATION:</b><br> Chris Joslin<br> Vice President of Operations<br> Mission3, Inc.<br> www.mission3.com<br> 602-957-2150 ext. 508<br> cjoslin@mission3.com<br> </P> Fri, 16 Mar 2007 21:21:00 GMT Mission3, Inc. <html> <p><b>FOR IMMEDIATE RELEASE</b></p> <p> <strong>Phoenix, AZ - May 22, 2007 - </strong>Mission3, Inc., a leading provider of project, document, and electronic submission management software specifically serving the Life Sciences industry announced today that its President and Founder, was featured in an exclusive ClinPage.com interview with Mark Uehling, Founder and Editor of <a href="http://www.clinpage.com/article/mission3_manages_ectds_projects/C9">ClinPage</a>, the premier online source of information about everything that supports clinical trials.</p> <p> The interview discusses the problems facing the Life Sciences industry as it deals with the vast quantities of clinical and regulatory data that are produced. Mission3 has responded to those unique problems through its enterprise software combination, MissionFire and FastCrossing, which blurs the line between a tool for electronic data management - and electronic project and submission management.</p> <p> "With the right preparation and process change, Mission3 believes it can save customers 10 percent of the process time from post-discovery through market availability. Put another way, that could mean six months to a year now wasted in compiling and preparing a variety of regulatory submissions and filings. And Mission3 is cheaper than the big, well-known names in the space. The software is web-based, meaning the IT department doesn't need to be troubled with installing it." said Mark Uehling, Founder and Editor of ClinPage.</p> <p> "Documents, projects, and regulatory submissions are like peas in a pod. We are looking at binding those systems together in an open, web services, modern architecture way. You can create relationships with those systems so data can flow automatically from one to the other." said Dirk Karsten Beth, President of Mission3.</p> <p> To read the full interview, please visit: <a href="http://www.clinpage.com/article/mission3_manages_ectds_projects/C9">http://www.clinpage.com/article/mission3_manages_ectds_projects/C9</a> </p> <p> <b>About Mission3, Inc.</b><br> Mission3 was founded to assist biotech, pharmaceutical, and medical device companies to bring needed therapies and devices to market quickly and efficiently. It's state-of-the-art enterprise software suite allows companies to manage projects and documents; comply with regulatory requirements; and submit applications in an automated, electronic, and managed environment. Companies taking full advantage of Mission3's industry leading enterprise suite can significantly reduce their time to market.</p> <p> <b>CONTACT INFORMATION:</b><br> Chris Joslin<br> Vice President of Operations<br> Mission3, Inc.<br> www.mission3.com<br> 602-957-2150 ext. 508<br> cjoslin@mission3.com<br> Tue, 22 May 2007 21:12:00 GMT Mission3, Inc. <html> <p> <b>FOR IMMEDIATE RELEASE</b></p> <p><b>Phoenix, AZ – August 8, 2007 –</b> Mission3, Inc., a leading provider of product lifecycle management software specifically serving the Life Sciences industry, today announced the renewal of their strategic partnership with TD2, the drug development arm of the Translational Genomics Research Institute (TGen). </p> <p>TD2 has fully deployed Mission3's product lifecycle management suite of MissionFire and FastCrossing to help organize and manage its drug development process. The suite facilitates collaboration between TD2's sponsors and investigators, allowing data and critical decisions to be managed in real time.</p> <p>"I couldn't be more pleased with our partnership," said Debbie Snyder, Vice President of Operations at TD2. "Having implemented MissionFire and FastCrossing has allowed TD2 to streamline operations and have insight into critical data and milestones during the development process. By deploying Mission3's product lifecycle management technology, TD2 is able to operate a system of competitive advantages that distinguishes us versus our competition." </p> <p>"Our relationship is unique and beneficial, as it has allowed Mission3 to gain access to critical real-world experience for product development and enhancements. The result of this collaboration allows us to bring to market substantially better solutions for product lifecycle management that are specifically tailored to the demanding needs to the life sciences industry. Our technology clearly changes the way that companies manage the drug development process. This relationship has been a win-win for all of us." said Dirk Karsten Beth, President of Mission3.</p> <p>More about Mission3's product lifecycle management suite can be viewed at <a href="http://www.mission3.com">http://www.mission3.com.</a></p> <p><b>About Mission3, Inc.</b><br> Mission3 is a leading provider of product lifecycle management software that specifically serves the unique needs of the life sciences industry. Its state-of-the-art on-demand software suite allows companies to manage projects and documents; comply with regulatory requirements; and submit applications in an automated, electronic, and regulatory compliant environment. Companies taking full advantage of Mission3's industry-leading innovative product lifecycle management suite can simultaneously create an electronic submission while a project is underway, significantly reducing the time and cost needed to develop a product and submit it for regulatory approval.</p> <p><b>About TD2</b><br> TD2 helps investigators from research institutions, biotech and pharmaceutical companies evaluate the efficacy of their drug candidate by using preclinical models, genomic tools and coordination of Phase I clinical trials at various clinical facilities, including Mayo Clinic Scottsdale, Scottsdale Healthcare, the Arizona Cancer Center, and U.S. Oncology. TD2 also provides central coordination of an international team of investigators who are conducting studies in patients with pancreatic cancer. Although initially focused in oncology, TD2 expects to expand its capabilities to other disease areas including neurological diseases and diabetes.</p> <p><b>CONTACT INFORMATION:</b><br> Chris Joslin<br> Vice President of Operations<br> Mission3, Inc.<br> www.mission3.com<br> 602-957-2150 ext. 508<br> cjoslin@mission3.com<br> <br> Amy Erickson<br> Office of Communications<br> Translational Genomics Research Institute (TGen) (602) 343-8522<br> aerickson@tgen.org </p> </html> Wed, 08 Aug 2007 16:54:00 GMT Mission3, Inc. <b>FOR IMMEDIATE RELEASE</b><br> <p> <b> Phoenix, AZ – September 24, 2007 –</b> Mission3, Inc., a leading provider of product lifecycle management software specifically serving the Life Sciences industry, announced today that is has introduced Mission3 OnDemand. Mission3 OnDemand is an innovative, enterprise grade Product Lifecycle Management Suite, offered via a Software-as-a-Service (SaaS) implementation that allows Life Sciences companies to manage projects, documents and global submissions of regulated products.</p> <p> Typical software provided to Life Sciences companies follows the expensive and staid enterprise model, which is often out of reach to many small and mid sized companies. Mission3 challenges that thinking by offering its pioneering PLM suite in a SaaS environment. Through Mission3 OnDemand, companies are able to realize key considerations in the adoption and implementation of mission critical software to speed up product development and regulatory submissions.</p> <p> "This further demonstrates our desire and commitment to provide all Life Sciences companies with the best possible software solutions so that they can get their products to market more rapidly than before." Said Dirk Karsten Beth, President and Founder of Mission3. "Deploying Mission3 OnDemand can help companies significantly reduce operating expenses related to R&D and the regulatory submission process, not to mention overall time to market."</p> <p> Mission3 OnDemand gives Life Sciences companies the ability to: <ul> <li>Collaborate – Internally and externally with partners, CROs, contractors and consultants</li> <li>Execute – View and make strategic decisions based on complete information of every task in the development process</li> <li>Submit – Save months of time by compiling the submission while work is underway. Submit globally with multiple indications and dosages with little additional effort. Manage complex submission tasks with ease.</li> <li>Reduce – Reduce the exhaustive regulatory processes of compiling submissions, formatting content, looking for the latest version of a document, asking who has done what.</li> <li>Comply – Comply with all CFR 21 Part 11 and predicate rules related to document management, cGXP, and Electronic Signatures. Comply with Global ICH and regional standards in submissions and submission documents.</li> <li>Create – Create corporate content in a managed and regulatory compliant framework. Automatically route documents through the approval process. Automatically create submission ready PDF files.</li> </ul> <p> <p> Breaking down typical barriers to adoption, such as hardware and IT staffing investments, by offering the software on a monthly basis, Mission3 is able to provide Life Sciences companies with economical solutions that allow them to manage documents and projects that are built around regulatory submissions.</p> <p> Industry analysts estimate that companies typically spend an additional $10 to implement enterprise software for every $1 spent purchasing it. Mission3 OnDemand allows small to mid-size companies to effectively employ the same IT infrastructure and services that are typically found in large size pharmaceutical and biotech companies, without the cost and complexity of typical enterprise software installations.</p> <p> <b>About Mission3, Inc.</b><br> Mission3 is a leading provider of product lifecycle management software that specifically serves the unique needs of the Life Sciences industry. Its state-of-the-art on-demand software suite allows companies to manage projects and documents, comply with regulatory requirements, and submit applications in an automated, electronic, and regulatory compliant environment. Companies taking full advantage of Mission3’s industry leading innovative product lifecycle management suite can simultaneously create an electronic submission while a project is underway, significantly reducing the time and cost needed to develop a product and submit it for regulatory approval.</p> <p> <b>CONTACT INFORMATION:</b><br> Chris Joslin<br> Vice President of Operations<br> Mission3, Inc.<br> <a href="http://www.mission3.com">www.mission3.com</a><br> 602-957-2150 ext. 508<br> <a href="mailto:cjoslin@mission3.com">cjoslin@mission3.com</a><br> </P> Mon, 24 Sep 2007 17:51:00 GMT Mission3, Inc. <p> <b>FOR IMMEDIATE RELEASE</b> </p> <p><b> Phoenix, AZ – October 25, 2007 – </b>Mission3, Inc., a leading provider of product lifecycle management software specifically serving the Life Sciences industry, announced today that a premier technical and strategic consulting firm to the pharmaceutical industry, has chosen Mission3 OnDemand for eCTD development, submissions, and lifecycle management.</P> <p> This professional services firm will be using Mission3 OnDemand to enable more efficient development and management of regulatory applications on behalf of its pharmaceutical clients. Professional Services organizations can expect to gain an increase in productivity in regulatory submission lifecycle management, while being able to collaborate more closely and easily with clients.</p> <p> "After an exhaustive review of the products currently available on the market, Mission3 offered the most robust, user friendly solution. It was easily implemented and quickly deployed. Mission3 offers the most desirable products available for our unique needs. As a bonus, we were able to train additional staff in the same week we deployed this solution." said the Managing Director</p> <p> "Mission3's development and implementation team was responsive in the fine tuning of the application so that we could accurately import existing customer submission and manage them electronically." said the client side Submissions Manager.</p> <p> "Our software suite enables professional services organizations to more completely service clients while improving the level of service offered. Taking full advantage of the synergies of Mission3 OnDemand, they can reduce operational expenses while increasing their top line revenue.", said Dirk Karsten Beth, President and Founder of Mission3.</p> <p><b> About Mission3, Inc.</b></br> Mission3 is a leading provider of product lifecycle management software that specifically serves the unique needs of the Life Sciences industry. Its state-of-the-art on-demand software suite allows companies to manage projects and documents; comply with regulatory requirements; and submit applications in an automated, electronic, and regulatory compliant environment. Companies taking full advantage of Mission3's industry leading innovative product lifecycle management suite can simultaneously create an electronic submission while a project is underway, significantly reducing the time and cost needed to develop a product and submit it for regulatory approval.</p> <p><b> CONTACT INFORMATION:</b><br> Chris Joslin<br> Vice President of Operations<br> Mission3, Inc.<br> www.mission3.com<br> 602-957-2150 ext. 508<br> cjoslin@mission3.com <br> </p> Thu, 25 Oct 2007 21:17:00 GMT Mission3, Inc. <html> <p> FOR IMMEDIATE RELEASE</p> <br> <p> <b>Phoenix, AZ – March 5, 2008 –</b> Mission3, Inc., a leading provider of product life cycle management software specifically serving the Life Sciences industry, announced today that ImmuneRegen BioSciences Inc. has chosen Mission3 OnDemand. ImmuneRegen will use Mission3 OnDemand as its technology infrastructure to manage and drive its product candidates through the development process and complete the regulatory submission life cycle.</p> <p> Mission3 OnDemand integrates project, document, and regulatory submission management into one simple to use, easy to deploy, web-based software suite that Life Sciences companies use to manage the development of product candidates from post discovery through regulatory submission.</p> <p> "We are excited to be working with a strong, growing company like ImmuneRegen. Given the nature of today’s industry, outsourcing plays a key role. Mission3 OnDemand provides ImmuneRegen with a secure, central collaboration platform where people outside their organization can contribute to research and product development effectively", said Dirk Karsten Beth, President and Founder of Mission3.</p> <p> Mission3 OnDemand organizes documents based on project structure, rather than in an arbitrary folder structure. Projects are dynamically tied to documents and as documentation is completed, real-time updates in project status are provided. Additionally, the documentation follows all ICH regulatory guidelines and flows seamlessly into corresponding regulatory submissions that can be electronically submitted and managed.</p> <p> "After a thorough review of the products on the market, we chose Mission3 OnDemand because it offers the best technology and value for a company like ours," said Michael Wilhelm, CEO of ImmuneRegen. "It was easy to setup and deploy and I can dynamically track projects with our labs and CROs. Real-time information is at my fingertips and quickly retrievable, whether I’m in the office, at home or traveling to visit with investors and analysts. Our scientists appreciate the version controls as well as its availability and security when dealing with different laboratories and vendors."</p> <p> <b>About ImmuneRegen BioSciences, Inc.</b></br> IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex® and Viprovex®, which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera(TM) is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at <a ahref="http://www.immuneregen.com">http://www.immuneregen.com.</a></p> <p> <b>About Mission3, Inc.</b><br> Mission3 is a leading provider of product lifecycle management software that specifically serves the unique needs of the Life Sciences industry. Mission3 OnDemand is a fully integrated, CFR 21 Part 11 compliant, Document, Project, and Regulatory Submission Management suite that is truly web-based and offered in an on-demand (SaaS) environment. It merges cutting edge technology with affordability, exclusively for Life Sciences Organizations. Designed for rapid deployment and ease of use, Mission3 OnDemand suite manages all documents within business areas governed by world wide regulatory bodies and corresponding submissions.</p> <p> <b>CONTACT INFORMATION:</b><br> Chris Joslin</br> Vice President of Operations<br> Mission3, Inc.<br> www.mission3.com<br> 602-957-2150 ext. 508<br> cjoslin@mission3.com<br> </p> <p> Michelle Laroche<br> Director of Operations<br> ImmuneRegen BioSciences, Inc.<br> www.immuneregen.com<br> 480-922-3926<br> mlaroche@immuneregen.com<br> </p> </html> Wed, 05 Mar 2008 15:26:00 GMT Mission3, Inc.